Lytix Biopharma Past Earnings Performance

Past criteria checks 0/6

Lytix Biopharma's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.4% per year.

Key information

-22.5%

Earnings growth rate

-11.2%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate18.4%
Return on equity-219.7%
Net Margin-752.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Lytix Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6BG Revenue, expenses and earnings (NOK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2411-812160
30 Jun 2414-762257
31 Mar 2415-862568
31 Dec 234-882463
30 Sep 2314-992462
30 Jun 2311-912362
31 Mar 2311-612250
31 Dec 2211-562046
30 Sep 228-432542
30 Jun 223-512542
31 Mar 224-632335
31 Dec 2119-483124
30 Sep 214-443030
30 Jun 217-403522
31 Mar 216-353519
31 Dec 204-422516
31 Dec 196-332314
31 Dec 1812-622240
31 Dec 1714-692447

Quality Earnings: 6BG is currently unprofitable.

Growing Profit Margin: 6BG is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6BG is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.

Accelerating Growth: Unable to compare 6BG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6BG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 6BG has a negative Return on Equity (-219.71%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies